Overview

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Status:
Recruiting

Trial end date:
2023-10-18

Target enrollment:

Participant gender:

Summary

This is a prospective, interventional, single arm, multicenter, phase 4 study to evaluate the clinical efficacy and safety of initiating Insulin glargine U300 in insulin-naive patients or switching from any other basal insulin to Insulin glargine U300 in insulin pre-treated patients with uncontrolled T2DM.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Insulin Glargine